<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>Biopharma News Feed - Oncology</title><link>https://nrouizem.github.io/test/oncology_feed.xml</link><description>Daily curated &amp; AI-summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/oncology_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Sat, 08 Mar 2025 01:06:22 +0000</lastBuildDate><item><title>The Oncology Market: 2025 Outlook</title><link>https://www.fiercebiotech.com/resource/oncology-market-2025-outlook</link><description>The article outlines four key trends expected to influence innovations, therapies, and the oncology market landscape in 2025 and beyond, emphasizing advancements in treatment and strategic industry shifts. It does not mention specific business deals, partnerships, mergers, or acquisitions, instead focusing on broader market dynamics analyzed in a whitepaper by Blue Matter Consulting.</description><pubDate>Tue, 25 Feb 2025 14:49:58 +0000</pubDate></item><item><title>BeiGene Gets Yet Another Label Expansion for PD-1 Drug Tevimbra</title><link>https://www.biospace.com/fda/beigene-gets-yet-another-label-expansion-for-pd-1-drug-tevimbra</link><description>BeiGene received approval for its drug as a first-line treatment for esophageal squamous cell carcinoma, following a recent label expansion for gastric and gastroesophageal cancers. The company is also advancing a pipeline of new cancer therapies, though the article does not mention any specific business deals, partnerships, mergers, or acquisitions.</description><pubDate>Tue, 04 Mar 2025 14:59:25 +0000</pubDate></item></channel></rss>
